BioCentury | Jan 13, 2020
Politics & Policy

Supreme Court declines to clean up its IP mess

...said its hands were tied by the Supreme Court’s decision in Mayo Collaborative Services v. Prometheus...
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...risk-sharing collaborations with pharma and biotech partners for drug development. Gastroenterology and autoimmune diseases company Prometheus...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...“Boundless Bio: Designing Cancer Therapies Around Extrachromosomal DNA “ ). Gastroenterology and autoimmune disease company Prometheus...
BioCentury | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

...see "Kidney is the New Liver" ). Prometheus, Takeda in IBD therapy, companion Dx deal Prometheus...
...Inc. partnered with Takeda to develop and commercialize three targeted IBD therapies and companion diagnostics. Prometheus...
...and validate three drug targets and develop and commercialize companion diagnostics for the resulting therapies. Prometheus...
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

...Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San...
...Inc. Cabaletta Bio Inc. Fulcrum Therapeutics Inc. Locate Bio Ltd. Modag GmbH NorthSea Therapeutics B.V. Spero Therapeutics Inc. Step Pharma S.A.S. Precision IBD Inc. Prometheus...
BioCentury | May 10, 2019
Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

...Supreme Court rulings involved diagnostics and personalized medicine. In the 2012 Mayo Collaborative Services v. Prometheus Laboratories Inc....
BioCentury | Mar 5, 2019
Financial News

Secura Bio closes $145M financing

...tranche of $50 million. Secura President and CEO Joseph Limber has held executive positions at Prometheus Laboratories Inc....
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...Corp. (NASDAQ: CELG), which Bristol-Myers Squibb Co. (NYSE:BMY) is acquiring. Wagman is a veteran of Prometheus Laboratories Inc....
BioCentury | Jan 25, 2019
Politics, Policy & Law

101 problems with patent eligibility

...Cravath, Swaine & Moore, formerly USPTO Since the 2012 Mayo Collaborative Sciences et al v. Prometheus Laboratories Inc....
BioCentury | Sep 29, 2018
Politics, Policy & Law

Patent law 101

...substances (see “ The Sky Isn’t Falling ”). In Mayo Collaborative Services et al. v. Prometheus Laboratories Inc....
...that informed drug administration decisions based on metabolite levels is an unpatentable law of nature. Prometheus...
Items per page:
1 - 10 of 194
BioCentury | Jan 13, 2020
Politics & Policy

Supreme Court declines to clean up its IP mess

...said its hands were tied by the Supreme Court’s decision in Mayo Collaborative Services v. Prometheus...
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...risk-sharing collaborations with pharma and biotech partners for drug development. Gastroenterology and autoimmune diseases company Prometheus...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...“Boundless Bio: Designing Cancer Therapies Around Extrachromosomal DNA “ ). Gastroenterology and autoimmune disease company Prometheus...
BioCentury | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

...see "Kidney is the New Liver" ). Prometheus, Takeda in IBD therapy, companion Dx deal Prometheus...
...Inc. partnered with Takeda to develop and commercialize three targeted IBD therapies and companion diagnostics. Prometheus...
...and validate three drug targets and develop and commercialize companion diagnostics for the resulting therapies. Prometheus...
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

...Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San...
...Inc. Cabaletta Bio Inc. Fulcrum Therapeutics Inc. Locate Bio Ltd. Modag GmbH NorthSea Therapeutics B.V. Spero Therapeutics Inc. Step Pharma S.A.S. Precision IBD Inc. Prometheus...
BioCentury | May 10, 2019
Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

...Supreme Court rulings involved diagnostics and personalized medicine. In the 2012 Mayo Collaborative Services v. Prometheus Laboratories Inc....
BioCentury | Mar 5, 2019
Financial News

Secura Bio closes $145M financing

...tranche of $50 million. Secura President and CEO Joseph Limber has held executive positions at Prometheus Laboratories Inc....
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...Corp. (NASDAQ: CELG), which Bristol-Myers Squibb Co. (NYSE:BMY) is acquiring. Wagman is a veteran of Prometheus Laboratories Inc....
BioCentury | Jan 25, 2019
Politics, Policy & Law

101 problems with patent eligibility

...Cravath, Swaine & Moore, formerly USPTO Since the 2012 Mayo Collaborative Sciences et al v. Prometheus Laboratories Inc....
BioCentury | Sep 29, 2018
Politics, Policy & Law

Patent law 101

...substances (see “ The Sky Isn’t Falling ”). In Mayo Collaborative Services et al. v. Prometheus Laboratories Inc....
...that informed drug administration decisions based on metabolite levels is an unpatentable law of nature. Prometheus...
Items per page:
1 - 10 of 194